MCRB
Seres Therapeutics, Inc.
$7.14
-1.00 (-12.29%)
At close · Jul 8
Market Cap
$68.45M
Shares
9,586,298
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$789K
FY2025
Net Income
$5.7M
+4088.2%
FY2025
Operating Margin
-11910.14%
FY2025
Diluted EPS
$0.64
FY2025
Operating Cash Flow
$1.12M
+100.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $789K | $0 | $0 | $7.13M | $144.93M | $33.22M | $34.51M | $28.27M | $32.1M | $21.77M | $0 | — | — | |
| — | — | — | — | — | — | — | — | — | $1.59M | $1.26M | $83K | — | — | |
| $50.43M | $49.06M | $64.6M | $117.6M | $109.65M | $141.89M | $90.57M | $80.14M | $95.96M | $89.46M | $81.99M | $38.1M | $10.72M | $4.81M | |
| $35.34M | $39.16M | $53.18M | $77.5M | $70.26M | $69.26M | $30.78M | $24.75M | $32.6M | $34.04M | $32.62M | $16.76M | $4.36M | $1.25M | |
| $3.84M | $4.13M | $5.47M | $6.24M | $6.63M | $5.95M | $6.58M | $7.6M | $7.86M | $7.26M | $4.21M | $728K | $190K | $88K | |
| — | $1.03M | — | $5.61M | — | $0 | $0 | $1.49M | $0 | $0 | — | — | — | — | |
| $88.79M | $94.76M | $121.32M | $195.1M | $179.91M | $209.42M | $121.35M | $106.38M | $128.55M | $123.5M | $114.61M | $54.86M | $15.08M | $6.05M | |
| -$87.64M | -$93.97M | -$121.32M | -$195.1M | -$179.91M | -$64.49M | -$88.13M | -$71.88M | -$100.28M | -$91.4M | -$92.84M | -$54.86M | -$15.08M | -$6.05M | |
| — | -11910.14% | — | — | -2524.05% | -44.5% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | — | — | — | |
| -$83.8M | -$89.84M | -$115.85M | -$188.85M | -$173.29M | -$58.55M | -$81.55M | -$64.27M | -$92.42M | -$84.14M | -$88.63M | -$54.13M | -$14.89M | -$5.96M | |
| $1.93M | $2.23M | $3.97M | $7.3M | $3.06M | $2.87M | $946K | $1.03M | $1.17M | $1.59M | — | — | — | — | |
| $40.74M | $99.67M | -$4.46M | $4.97M | -$3.67M | -$1.09M | -$997K | $1.6M | $1.34M | $2.02M | $1.26M | $76K | -$1.63M | -$50K | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$46.9M | $5.7M | $136K | -$113.72M | -$250.16M | -$65.58M | -$89.13M | -$70.28M | -$98.94M | -$89.38M | -$91.58M | -$54.78M | -$16.71M | -$6.1M | |
| — | 721.93% | — | — | -3509.5% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | — | — | — | |
| -$46.9M | $5.7M | $136K | -$113.72M | -$250.16M | -$65.58M | -$89.13M | -$70.28M | -$98.94M | -$89.38M | -$91.58M | -$54.78M | -$18M | -$6.98M | |
| — | $5.7M | $136K | -$113.71M | -$250.11M | -$65.59M | -$89.17M | -$70.28M | -$98.8M | -$89.38M | -$91.76M | -$54.75M | -$18M | -$6.98M | |
| USD/shares | — | $0.64 | $0.00 | -$17.77 | -$46.20 | -$14.40 | -$22.40 | — | — | — | — | — | — | — |
| USD/shares | — | $0.64 | $0.00 | -$17.77 | -$46.20 | -$14.40 | -$22.40 | — | — | — | — | — | — | — |
| shares | — | 8.86M | 7.77M | 6.4M | 5.4M | 4.59M | 3.99M | 2.83M | 2.04M | 2.02M | 1.99M | 1.18M | 337.4K | 319.75K |
| shares | — | 8.87M | 7.77M | 6.4M | 5.4M | 4.59M | 3.99M | 2.83M | 2.04M | 2.02M | 1.99M | 1.18M | 337.4K | 319.75K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.